CMO Recipharm plots a $142M Swedish IPO

Amid the prolonged bull market for life sciences IPOs, a handful of European firms are lining up to test the waters in Europe, including CMO giant Recipharm, which is planning to stage a $142 million offering. The company expects to make its debut on the Swedish market next month, giving it a market cap of up to $500 million. Article

Suggested Articles

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.

Aetion has raised $50 million so far, and it plans to enhance its platform to support more complex therapeutic areas and expand its team.

Charles River partners with PathoQuest to offer clients NGS solutions for biologics viral contamination testing and cell-line genetic characterization.